A Phase 1 interventional study of XmAb412 Monoclonal Bispecific Antibody and Placebo in Not Applicable - Healthy Adult Participants, sponsored by Xencor, Inc.. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Xencor, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Inflammatory Bowel Diseases with a site in Australia — 11 open to participants now, 13 under way, 3 of them phase 3. Inflammatory Bowel Diseases · Australia.
Among the 54 studies in Inflammatory Bowel Diseases with a site in Australia, this one is the 26th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 in phase 1, reaches primary completion later than 6 of the 12 other live ones, and was the 53rd registered.
1,552 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.
Browse Inflammatory Bowel Diseases studies →11 of the 54 studies in Inflammatory Bowel Diseases with a site in Australia are open now. Recruiting first, the newest first:
Austin Health · Sites in Australia
Ages 18+ · Women only
Parvus Therapeutics, Inc. · Sites in Australia
Ages 18–65 · Healthy volunteers
Odyssey Therapeutics · Sites in Australia, Austria, Canada and 7 more countries
Ages 18–75
Spyre Therapeutics, Inc. · Sites in Australia, United States, Argentina and 33 more countries
Ages 18–75
Xencor, Inc. · Sites in Australia, United States, Argentina and 16 more countries
Ages 18–75 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 275 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 20 · Phase 3 18 · Phase 4 2
First in 2005; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 128 is above the median of 68 across 872 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 139 across the 49 interventional studies, 119 across the 5 observational. Of the 36 that completed or were terminated, 22 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 54 have an industry lead sponsor. The 10 most frequent:
Xencor, Inc. is the lead sponsor of 30 studies on the registry; 7 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 2 (13%) have results posted.
Xencor, Inc. has 2 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Inflammatory Bowel Diseases with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07012395Spyre Therapeutics, Inc.A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | 2027-06 |
| NCT07713485Xencor, Inc.Study of XmAb412 in Healthy Participants | 2027-08 |
| NCT07423000Parvus Therapeutics, Inc.A Phase 1 Study of PVT401 in Healthy Subjects | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Inflammatory Bowel Diseases with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants
This study consists of 2 parts, as follows:
In Part A, participants will receive a single dose of XmAb412 using subcutaneous (SC) or intravenous (IV) administration route.
In Part B, participants will receive multiple doses of XmAb412 or placebo using SC or IV administration route.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active XmAb412 to be administered to healthy adult participants.
Drug: XmAb412 Monoclonal Bispecific Antibody
Placebo Comparator to be administered to healthy participants.
Drug: Placebo
Active XmAb412 to be administered to healthy participants.
Drug: XmAb412 Monoclonal Bispecific Antibody
Placebo Comparator to be administered to healthy participants.
Drug: Placebo
Monoclonal Bispecific Antibody
Placebo
Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of XmAb412 in healthy adult participants (Part A and Part B)
Time frame: Up to 28 weeks
Serum PK parameters of XmAb412 in healthy adult participants (Part A and Part B)
Time frame: Up to 28 weeks
Cmax (Maximum concentration of drug)
Time frame: Up to 28 weeks
Tmax (Time of maximum concentration of drug)
Time frame: Up to 28 weeks
• AUC0-last (Area under the curve drug concentration-time curve to last concentration)
Time frame: Up to 28 weeks
• Repeat dose cohorts: AUC0-tau (AUC within a dosing interval
Time frame: Up to 28 weeks
• AUC0-inf (AUC from time 0 extrapolated to infinity
Time frame: Up to 28 weeks
• t1/2 (terminal elimination half-life
Time frame: Up to 28 weeks
• CL/F (apparent) total body clearance
Time frame: Up to 28 weeks
• Vz/F (apparent volume of distribution
Time frame: Up to 28 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Aug 2027, 13 months after the start.
Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's planned 13 months is above that.
Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion May 2027 → Aug 2027 and completion Mar 2028 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.